Please login to the form below

Will COVID-19 necessitate a change in thinking around clinical trials?

The global outbreak of coronavirus (COVID-19) and current misinformation infiltrating our consciousness on social media has been a challenge to get our heads around, but it’s undeniable that there’s a public health risk currently proposed by the pandemic. With Italy in lockdown and other countries possibly following suit, will this outbreak impact ongoing clinical studies and those currently enrolling patients?

At the time of writing, it’s unknown how coronavirus spreads from person to person. It’s possible it spreads in cough droplets, like similar viruses. If an individual is advised to self-isolate, whether due to contracting the virus, or coming into contact with someone who has the virus, this will likely have a knock-on effect on clinical studies. People who are currently participating in clinical trials will be unable to attend appointments, and potential participants will be unable to be screened and more hesitant about joining.

The challenge with any clinical study is that every site visit is dictated by the protocol, which has been EC/IRB approved. However, there are options to improve participation that account for the current pandemic:

  • Increase opportunities to part by decentralising: introduce home visits or facilitate assessments through technology platforms
  • Partner with pharmacies and local health settings, who could assist with procedures such as blood tests
  • Post the investigative therapy directly to participants’ homes

These solutions are quick fixes that can ease the burden on healthcare and ensure clinical studies progress without disruption, but any protocol changes will need to be reported for EC/IRB approvals. For instance, the FDA regulations state:

“Each IRB must follow written procedures for ensuring prompt reporting to the IRB of proposed changes in a research activity, and ensuring that changes in approved research, during the period for which IRB approval has already been given, may not be initiated without IRB review and approval except where necessary to eliminate apparent immediate hazards to the human subjects.”

Considering coronavirus is an immediate threat to the safety of people, it is grounds to make the appropriate changes to the study. IRBs should be notified as soon as possible to ensure changes are documented. If you have questions, please contact your local IRB representative and they should be able to help.

The coronavirus has raised some interesting points: why aren’t more studies partially decentralised? Why are pharmacies not able to do blood tests? Why is the investigational drug not shipped to the participant?

The clinical research industry should take learnings from this epidemic, have a period of introspection and work on improving the experience of sites and participants.

This blog was first published here: https://www.couchhealth.co/post/will-covid-19-have-a-short-term-impact-on-clinical-studies

14th March 2020

Share

Tags

Company Details

COUCH Health

+44 (0) 330 995 0656

Contact Website

Address:
Suite 2.10, Jactin House
24 Hood Street
Manchester
M4 6WX
United Kingdom

Latest content on this profile

INFOGRAPHIC 02: The Importance of clinical study websites
Here’s a infographic of why clinical study websites are important to patient recruitment and retention strategies…
COUCH Health
WHITE PAPER 05: Improving the effectiveness of clinical trial recruitment materials
With exclusive research conducted by COUCH Health, gain insight into clinical trial recruitment materials best practice.
COUCH Health
Demand Diversity Podcast
The unacceptable lack of diversity among clinical research participants would suggest that we are.As we begin our campaign to demand diversity in the clinical research space, we invite you to listen up and really tune in to the reality of why and where our industry is failing in respect of diversity and inclusion.We’ve kept our podcast series jam-packed with genuine insights from the general public across a variety of cultural and religious backgrounds. Ready to listen what they have to say?The press play here: https://www.demanddiversity.co/podcast
COUCH Health
DEMAND DIVERSITY REPORT 01: Exploring attitudes towards clinical research among people from different ethnic groups in the UK
This report reveals insights from the people themselves, and discusses the starting points for overcoming current challenges.
COUCH Health
COUCH Health demands the clinical research industry improves participant diversity
As advocates of diverse and inclusive clinical trials, patient engagement agency COUCH Health is calling on the industry take action to make clinical research more inclusive and representative of all populations. Demand Diversity has launched with the aim to raise awareness of the lack of diversity in clinical research, and make change happen.
COUCH Health
5 creative tactics for your patient recruitment strategies
For effective clinical trial recruitment strategies, understanding the challenges related to recruitment and retention of clinical trial participants is one thing, but it’s important to find innovative solutions to the problem.
COUCH Health